Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

HNSCC: Update Bulletin [November 2017]

Product Code:
596200747
Publication Date:
November 2017
Format:
PDF
Price:
£910

Gain new KOL insights on the latest events happening in head and neck squamous cell carcinoma (HNSCC), including; data from a Phase Ib trial of Roche’s anti–PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) in patients with advanced HNSCC which were presented at the European Society for Medical Oncology 2017 Congress (ESMO 2017); positive findings from the Phase II HAWK study of AstraZeneca’s durvalumab (Imfinzi) in patients with recurrent/metastatic HNSCC who express high levels of PD-L1 which were also presented at ESMO 2017; and updated findings released from the Phase III CheckMate-141 trial which suggest tumour shrinkage when Bristol-Myers Squibb’s (BMS’) Opdivo (nivolumab) is continued in patients with recurrent/metastatic HNSCC who had previously progressed on Opdivo.

Business Questions:

• How do KOLs interpret the early data for atezolizumab in HNSCC?
• Where does the most significant opportunity for atezolizumab in HNSCC lie?
• What could help differentiate atezolizumab from other immune checkpoint inhibitors in an increasingly competitive space?
• How do KOLs view the data from the Phase II HAWK study of durvalumab?
• How do KOLs interpret the enhanced efficacy of durvalumab in HPV-positive HNSCC observed in the HAWK trial?
• What will be the major determinant of durvalumab’s success in HNSCC?
• How do KOLs view the updated findings from the CheckMate-141 trial on continuing Opdivo beyond progression in HNSCC, and will these results influence treatment practice?
• Will the updated findings from the CheckMate-141 trial confer an advantage to Opdivo, relative to Keytruda, in HNSCC?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved